Table 1.
Intracranial Efficacy of Novel Targeted Therapies in Non-small cell lung cancer (NSCLC) with Emerging Fusion Drivers.
| Drug | Intracranial Efficacy | Overall Efficacy | Trial | Reference |
|---|---|---|---|---|
| RET fusions | ||||
| Selpercatinib | 10/11 (91%) pts with response | ORR 68% (71/105 pts) | LIBRETTO-001 | [49] |
| Pralsetinib | 7/9 (78%) pts with response | ORR 58% (28/48 pts) | ARROW | [50] |
| NTRK fusions | ||||
| Entrectinib | 4/6 (67%) pts with response | ORR 70% (7/10 pts) | ALKA-372-001, STARTRK-1, STARTRK-2 | [69] |
| Larotrectinib | 1/3 (33%) pts with response 2/3 (67%) pts with stable disease |
ORR 71% (5/7 pts) | Phase 1, SCOUT, NAVIGATE | [72] |
| NRG1 fusions | ||||
| MCLA-128 | Case report of response in 1 pt | - | SPP | [84] |
ORR—objective response rate, Pts—patients, SPP—single patient protocol.